Eupraxia Pharmaceuticals Files 6-K with Press Release
Ticker: EPRX · Form: 6-K · Filed: May 23, 2024 · CIK: 1581178
Sentiment: neutral
Topics: foreign-private-issuer, press-release, regulatory-filing
TL;DR
Eupraxia Pharma dropped a 6-K with a press release today. Check it out.
AI Summary
Eupraxia Pharmaceuticals Inc. filed a Form 6-K on May 23, 2024, reporting as a foreign private issuer. The filing includes a press release dated May 23, 2024, as Exhibit 99.1. The company is incorporated in Canada and its principal executive offices are located in Victoria, British Columbia.
Why It Matters
This filing provides an update from Eupraxia Pharmaceuticals, potentially containing material information for investors regarding the company's operations or strategic developments.
Risk Assessment
Risk Level: low — This filing is a routine report of a foreign private issuer and does not appear to contain significant new financial or operational disclosures that would immediately alter risk.
Key Players & Entities
- Eupraxia Pharmaceuticals Inc. (company) — Registrant
- May 23, 2024 (date) — Filing date and press release date
- Bruce Cousins (person) — Signatory for the filing
- Victoria, British Columbia, Canada (location) — Company's principal executive offices
FAQ
What is the primary purpose of this Form 6-K filing?
The primary purpose of this Form 6-K filing is to report information that Eupraxia Pharmaceuticals Inc. has made or is required to make public in Canada, filed or made public outside the United States, or filed or made public with any stock exchange on which its securities are traded, as required for a foreign private issuer.
What specific document is included as part of this report?
Exhibit 99.1, a Press Release dated May 23, 2024, is included as part of this report.
Where are Eupraxia Pharmaceuticals Inc.'s principal executive offices located?
Eupraxia Pharmaceuticals Inc.'s principal executive offices are located at 201-2067 Cadboro Bay Road, Victoria, British Columbia, Canada V8R 5G4.
Does Eupraxia Pharmaceuticals Inc. file annual reports under Form 20-F or Form 40-F?
Eupraxia Pharmaceuticals Inc. files annual reports under Form 40-F.
Who signed this Form 6-K on behalf of Eupraxia Pharmaceuticals Inc.?
Bruce Cousins signed this Form 6-K on behalf of Eupraxia Pharmaceuticals Inc.
Filing Stats: 169 words · 1 min read · ~1 pages · Grade level 14.2 · Accepted 2024-05-23 17:04:24
Filing Documents
- form6k.htm (6-K) — 11KB
- ex991.htm (EX-99.1) — 24KB
- logo.jpg (GRAPHIC) — 23KB
- 0001279569-24-000662.txt ( ) — 68KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Eupraxia Pharmaceuticals Inc. Date: May 23, 2024 By: /s/ Bruce Cousins Name: Bruce Cousins Title: President and Chief Financial Officer